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AbstrAct
Chronic inflammation is strongly associated with prostate cancer pathogenesis. 
Transducin β-like protein (TBL1) and Transducin β-like 1X-linked receptor 1 (TBLR1) 
have been identified recently as a coactivator for NF-κB-mediated transcription; 
however, the underlying mechanism by which TBL1 and TBLR1 activate NF-κB 
function during inflammation remains unknown. Here, we demonstrate that cytokine 
production is significantly elevated in androgen-independent PC-3 prostate cancer 
cells compared with androgen-dependent LNCaP prostate cancer cells. Elevated 
cytokine production positively correlates with the TBL1 and TBLR1 SUMOylation level 
in PC-3 cells. We show that both TBL1 and TBLR1 are SUMOylated in response to 
TNF-α treatment, and this increases formation of the TBL1-TBLR1-NF-κB complex, 
which leads to NF-κB-mediated transcriptional activation of cytokine gene expression. 
Conversely, SENP1-mediated deSUMOylation of TBL1 and TBLR1 inhibits NF-κB-target 
gene expression by dissociating TBL1 and TBLR1 from the nuclear hormone receptor 
corepressor (NCoR) complex. TBL1 knockdown substantially suppresses inflammatory 
signaling and PC-3 cell proliferation. Collectively, these results suggest that targeted 
SUMOylation of TBL1 and TBLR1 may be a useful strategy for therapeutic treatment 
of androgen-independent prostate cancer. 
INtrODUctION
Chronic inflammation leads to a wide variety of 
diseases, such as rheumatoid arthritis, other autoimmune 
disorders, cardiovascular disease, gastrointestinal disorders, 
and several cancers [1, 2]. Prostate cancer (PCa) is the most 
commonly diagnosed malignancy in men [3, 4]. Chronic 
inflammation is one of the most important factors in 
prostate cancer etiology and carcinogenesis, and plasma 
IL-6 level has prognostic significance in patients with 
hormone-refractory prostate cancer [5, 6]. Recently, a five-
year follow-up study for men who had abnormal serum 
prostate-specific antigen (PSA) levels and/or digital rectal 
examinations (DRE) reported that chronic inflammation is a 
significant risk factor in the development of prostate cancer 
[7]. Therefore, blocking inflammatory signaling may be a 
useful strategy for treating malignant prostate cancer.
NF-κB is a pleiotropic transcription factor that 
controls the expression of numerous genes encoding 
cytokines, angiogenesis modifiers, cell adhesion molecules, 
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and anti-apoptotic factors [8]. The mammalian NF-κB 
family has five members: RelA (p65); NF-κB1 (p50, p105); 
NF-κB2 (p52, p100); c-Rel; and RelB. The most abundant 
activated form of NF-κB is a heterodimer that contains p65 
and p50 subunits. NF-κB is located in the cytoplasm along 
with its inhibitor protein IκB. Inflammatory stimuli promote 
IκB degradation, which enables NF-κB translocation 
to the nucleus and binding to target gene promoters that 
regulate transcription of the pro-inflammatory cytokines. 
NF-κB is highly activated at sites of inflammation in 
multiple human cancers. There is accumulating evidence 
that NF-κB activation is correlated with prostate cancer 
development, prognosis, and castrate-resistant progression 
[9–12]. Cytokine IL-6 stimulates prostate cancer growth 
by stimulating the androgen receptor, and is involved in 
the development of bone metastasis [13]. Increased levels 
of NF-κB and IL-6 are implicated in the development of 
prostate cancer cell chemoresistance [14]. These combined 
studies suggest that NF-κB may be a promising target for 
improving chemotherapeutic efficacy in prostate cancer.
TBL1 and TBLR1, which are components of the 
nuclear hormone receptor corepressor (NCoR)/silencing 
mediator for retinoid and thyroid hormone receptors 
(SMRT) corepressor complexes, contain a Lis1 homology 
domain (LisH)/WD-40 motif, and have approximately 
86% identity [15, 16]. Recent studies report that TBL1 
and TBLR1 stabilize the quaternary structure of the 
NCoR/SMRT corepressor complex and bind to the tails of 
hypoacetylated histones H2B and H4, which target NCoR/
SMRT complexes to chromatin [17]. The LisH domains 
of both TBL1 and TBLR1 are reported to be required 
for oligomerization, and contribute to the stable binding 
of NCoR/SMRT corepressor complexes to chromatin to 
completely repress target gene expression [18]. These 
results suggest that TBL1 and TBLR1 have important 
role in class I HDAC corepressor complex-mediated 
transcriptional repression. However, TBL1 and TBLR1 
also were found to function as E3 ubiquitin ligase adaptors. 
In this capacity, they recruit the ubiquitin-conjugating/19S 
proteasome complex to the corepressor complex, which 
leads to corepressor degradation, and mediates the 
exchange of corepressors for coactivators in response to 
ligand binding/stimulation. These actions lead to specific 
nuclear receptor-mediated gene activation events [19, 20]. 
TBL1, TBLR1, and β-catenin recruit one another to Wnt 
target gene promoters to activate transcription in response 
to canonical Wnt signaling, and reversible SUMOylation 
of TBL1 and TBLR1 regulates β-catenin-mediated Wnt 
signaling [21, 22]. TBL1 is required for p65 recruitment 
to NF-κB target gene promoters in response to tumor 
necrosis factor alpha (TNF-α) [23]. These results suggest 
that TBL1 and TBLR1 function as transcriptional 
coactivators, and may have a role in the transcriptional 
activation of NF-κB target genes. However, the detailed 
mechanism of NF-κB-mediated transcriptional activation 
by TBL1 and TBLR1 corepressors was unknown.
In this study, we found that constitutive cytokine 
elevation in the androgen-independent prostate cancer 
(AIPC) cell lines PC-3 and C4-2B correlates with 
the SUMOylation levels of TBL1 and TBLR1. TBL1 
and TBLR1 are SUMOylated in vivo in response to 
inflammatory stimuli. TBL1 and TBLR1 SUMOylation 
dissociate TBL1 and TBLR1 from the NCoR/HDAC3 
corepressor complexes and induces formation of the 
TBL1SUMO-TBLR1SUMO-NF-κB complex, which ultimately 
leads to transcriptional activation of NF-κB target genes. 
Therefore, this study suggests a regulatory mechanism 
for elevated NF-κB-mediated inflammatory signaling in 
AIPCs via reversible SUMOylation of TBL1 and TBLR1.
rEsULts
tbL1 and tbLr1 sUMOylation and 
inflammatory cytokines are elevated in AIPC 
cells
NF-κB is constitutively activated in prostate tumors 
and cell lines [5]. Therefore, we first examined the 
inflammatory cytokine levels in prostate cancer cell lines 
by performing cDNA microarrays using the androgen-
dependent prostate cancer (ADPC) cell line LNCaP and 
the AIPC cell line PC-3. In agreement with a previous 
report [24], we observed that the pro-inflammatory 
cytokines IL-8, IL-1β, and IL-6 were strongly elevated 
in PC-3 cells compared with LNCaP cells (Figure 1A). 
Quantitative RT-PCR analysis verified the elevated 
cytokine levels in PC-3 cells (Figure 1B).
A recent study reported that the TBL1 corepressor 
acts as a cofactor for recruiting p65 to NF-κB target gene 
promoters, which eventually leads to the transcriptional 
activation of inflammatory cytokines [23]. Therefore, 
we explored the possibility that TBL1 and TBLR1 are 
involved in cytokine elevation in AIPC cells. First, we 
assessed TBL1 and TBLR1 levels in prostate cancer cells 
by performing western blot analysis. Immunoprecipitation 
analysis revealed that the interaction between TBL1/
TBLR1 and RelA in PC-3 cells was strongly increased 
compared with that in LNCaP cells, and the TBL1 and 
TBLR1 protein levels in PC-3 cells also were higher 
than those in LNCaP cells (Figure 1C, left panel). TBL1 
and TBLR1 SUMOylation caused TBL1 and TBLR1 
dissociation from the NCoR corepressor complex [21]. 
Therefore, we next examined the relative association 
of TBL1 and TBLR1 with NCoR/HDAC3 corepressor 
complexes in PC-3 and LNCaP cells. TBL1 and TBLR1 
association with NCoR/HDAC3 corepressor complexes 
were significantly lower in PC-3 cells than in LNCaP 
cells (Figure 1C, left panel). To verify these results, we 
performed Duo-link in situ proximity ligation assay (PLA) 
analysis, which enables the detection of protein interactions 
and modifications, and verified elevated SUMOylation 
levels of endogenous TBL1 in PC-3 cells (Figure 1D).
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Due to their high metastatic potential resulting from 
their androgen-insensitive state, PC-3 cells have been less 
extensively studied than LNCaP cells for investigating 
biochemical changes in advanced prostate cancer. PC-3 
cell line was established from bone metastasis of prostate 
cancer. Therefore, we selected the bone metastasis subline 
C4-2B, which was generated from parental LNCaP cells, 
to confirm whether these similar cell lines share the same 
biochemical features as PC-3 cells. The results showed 
that inflammatory cytokine levels were highly elevated 
in C4-2B cells compared with those in LNCaP cells, 
which was similar to the observed cytokine levels in PC-3 
cells. The levels of TBL1 and TBLR1 SUMOylation 
and association of TBL1 and TBLR1 with RelA were 
higher in C4-2B cells than in PC-3 cells (Figure 1C, right 
panel). Collectively, these results suggest that constitutive 
activation of inflammatory signaling in AIPC cells 
correlates with TBL1 and TBLR1 SUMOylation.
Inflammatory stimulation promotes TBL1 and 
tbLr1 sUMOylation
Recent work showed that SUMO modification 
acts as a molecular switch that regulates corepressive 
and coactive functions of TBL1 and TBLR1 during Wnt 
signaling activation [21]. Therefore, we examined whether 
TBL1 and TBLR1 SUMOylation increases in response to 
inflammatory activation. Myc-TBL1 or Myc-TBLR1 was 
co-transfected with Flag-SUMO1 into PC-3 cells, the cells 
were treated with TNF-α, and immunoprecipitation assays 
were performed. In response to treatment, SUMOylation 
of both TBL1 and TBLR1 increased in response to TNF-α 
treatment (Figure 2A and Figure S1A). Our previous work 
showed that TBL1 and TBLR1 were SUMOylated on 
lysine 560 and lysine 497, respectively, during activation 
of Wnt signaling [21]. Therefore, we examined whether 
the TNF-α-mediated TBL1 SUMOylation site was 
identical with the Wnt signaling-induced SUMOylation 
site. The results indicated that TBL1K560R and TBLR1K497R 
mutants failed to form complexes with SUMO1, whereas 
wild-type TBL1 and TBLR1 did form SUMO1 complexes 
(Figure 2B and Figure S1B). These data confirm that TBL1 
and TBLR1 are SUMOylated at Lys560 and Lys497, 
respectively, in response to inflammatory signaling.
The SUMO-processing enzyme SENP1 mediates 
deSUMOylation of TBL1 and TBLR1 [21]. We examined 
whether SENP1 deSUMOylates TBL1 and TBLR1. SENP1 
efficiently removed SUMO from TBL1 and TBLR1, 
whereas inactive SENP1C603S had negligible deSUMOylation 
activity on TBL1 and TBLR1 (Figure 2C and Figure S1C, 
lane 4 versus lane 5). We observed the same effects of 
SENP1 in deSUMOylation of endogenous TBL1 and 
TBLR1 (Figure 2D).
To corroborate inflammatory signaling-dependent 
TBL1 SUMOylation in vivo, we performed in situ PLA 
analysis by transfecting Flag-tagged SENP1WT (wild-type) or 
SENP1C603S (inactive mutant) into PC-3 cells. Consistently, 
endogenous TBL1 in PC-3 cells was efficiently SUMOylated 
in response to TNF-α. Ectopic expression of SENP1WT 
efficiently reversed TNF-α-induced TBL1 SUMOylation, 
whereas SENP1C603S overexpression had a negligible effect 
on TNF-α-induced TBL1 SUMOylation (Figure 2E). 
These combined results indicate that TBL1 and TBLR1 are 
SUMOylated in response to inflammatory stimuli, and are 
deSUMOylated by SENP1.
TBL1 SUMOylation enhances NF-κB-mediated 
transcription 
Inflammatory cytokines and SUMOylated TBL1/
TBLR1 are highly elevated in PC-3 cells. Therefore, 
we examined the effect of TBL1 SUMOylation on NF-
κB-mediated transcription of cytokine genes. Ectopic 
expression of SUMO-conjugated TBL1 enhanced TNF-
α-induced IL-8 and IL-1β gene transcription compared 
to that of unconjugated TBL1 (Figure 3A). Expression 
of SENP1WT efficiently reversed the effect of Sumo-
conjugated TBL1, whereas expression of inactive 
SENP1C603S failed to reverse the effect (Figure 3B). 
These combined results indicate a crucial role for TBL1 
SUMOylation in NF-κB-mediated activation of cytokine 
gene transcription.
Next, we tested whether TBL1 or TBLR1 
knockdown suppresses transcriptional activation of 
cytokine gene expression in PC-3 cells. Treatment of 
PC-3 cells with either siTBL1 or siTBLR1 substantially 
reduced the basal levels of IL-8 and IL-1β (Figure 3C). 
Treatment of PC-3 cells with TNF-α time-dependently 
increased IL-8 and IL-1β gene expression; however, TBL1 
knockdown greatly reduced TNF-α-dependent cytokine 
gene expression in PC-3 cells (Figure 3D). Consistently, 
overexpression of SENP1WT, but not SENP1C603S, 
efficiently suppressed the cytokine transcript levels in 
PC-3 cells (Figure 3E), indicating that TBL1 and TBLR1 
SUMOylation constitutively enhance inflammatory 
cytokine production in PC-3 cells.
Inflammatory stimulation induces formation 
of the TBL1sUMO-TBLR1sUMO-NF-κB activator 
complex
SUMOylation induces TBL1 and TBLR1 disso-
ciation from the NCoR corepressor complex, which 
corresponds with formation of the TBL1-TBLR1-β-
catenin coactivator complex [21]. Therefore, we examined 
whether SUMOylation increases formation of the TBL1-
TBLR1-NF-κB complex in response to TNF-α treatment. 
TNF-α treatment increased the association of wild-type 
TBL1 with NF-kB (greek letter), whereas TNF-α reduced 
the interaction between TBL1 and HDAC3 or NCoR 
(Figure 4A). Figure S2 showed same effect of TNF-α 
on TBLR1 with NF-κB, HDAC3 or NCoR association. 
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Figure 1: SUMOylation of TBL1 and TBLR1 is strongly elevated in androgen-independent prostate cancer cells 
enriched with inflammatory cytokines. (A) Inflammatory cytokine levels are higher in PC-3 cells than in LNCaP cells. Changes in 
mRNA expression were evaluated by cDNA microarray analysis using the Illumina HumanRef-8 v3 Expression BeadChip. (b) Validation 
of cDNA microarray analysis by quantitative real-time PCR. Expression levels of each gene were analyzed by quantitative RT-PCR. 
Statistical significance was determined using Student’s t-test; #P < 0.01 versus LNCaP cell lines. (c) SUMOylation of TBL1 and TBLR1 
levels are higher in PC-3 and C4-2B cells than in LNCaP cells. Immunoprecipitation analysis was performed using cell lysates, and 
immunoblotting was performed using the indicated antibodies. (D) Validation of TBL1 SUMOylation in vivo in LNCaP and PC-3 cells. 
Duo-link in situ PLA analysis was performed as described in Materials and methods with the indicated antibodies.
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Figure 2: SENP1 suppresses TNF-α-induced TBL1 SUMOylation. (A) TNF-α treatment induces TBL1 SUMOylation. PC-3 
cells were co-transfected with indicated plasmids. Cells were treated with TNF-α for indicating time point and then harvested. Cell lysates 
were immunoprecipitated and subsequently immunoblotted with the indicated antibodies. (b) TNF-α induces SUMOylation of TBL1 at 
Lys560. Cells were co-transfected for 48 hours, treated with TNF-α for 1 hour and then harvested. Cell lysates were immunoprecipitated 
and subsequently immunoblotted with the indicated antibodies. (c) SENP1 deSUMOylates TBL1. (D) SENP1 suppresses TNF-α-induced 
SUMOylation of endogenous TBL1 and TBLR1. Cell lysates were immunoprecipitated and subsequently immunoblotted with the indicated 
antibodies. (E) Validation of SENP1-mediated TBL1 deSUMOylation in vivo in PC-3 cells. Permeabilized PC-3 cells were treated with 
TNF-α (10 ng/ml) for 1 hour and incubated with anti-TBL1 antibody, anti-SUMO antibody, and PLA probes (PLUS and MINUS).
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Figure 3: SENP1 inhibits TNF-α-induced NF-κB activation via deSUMOylation of TBL1 and TBLR1. (A) TBL1 
SUMOylation potentiates its coactive function for NF-κB during inflammatory signaling. PC-3 cells were co-transfected with indicated 
plasmids for 48 hours and treated with 10 ng/ml TNF-α for 2 hours. Target gene mRNA levels were analyzed by qRT-PCR. Cell lysates were 
immunoblotted with the indicated antibodies. Statistical significance was determined using Student’s t-test; *P < 0.05 and #P < 0.01 versus 
treatment with TNF-α. (b) SENP1 reverses the effect of TBL1 SUMOylation on TNF-α-induced NF-κB activation. Co-transfected PC-3 
cells were treated with TNF-α for 2 hours, mRNA levels were analyzed by qRT-PCR. Cell lysates were immunoblotted with the indicated 
antibodies. Statistical significance was determined using Student’s t-test; *P < 0.05 and #P < 0.01 versus treatment with TNF-α. (c) TBL1 
or TBLR1 knockdown reduces cytokine levels in PC-3 cells. Cells were transfected with siRNA against TBL1 or TBLR1, and target gene 
mRNA levels were analyzed by qRT-PCR. Statistical significance was determined using Student’s t-test; *P < 0.05 and #P < 0.01 versus 
transfection with siControl. (D) TBL1 knockdown greatly reduces TNF-α-induced cytokine production in PC-3 cells. Lentiviral shTBL1-
infected cells were treated with TNF-α, harvested, and mRNA levels were analyzed by qRT-PCR. Statistical significance was determined 
using Student’s t-test; #P < 0.01 versus infection with shControl samples. (E) SENP1 overexpression reduces cytokine levels in PC-3 cells. 
PC-3 cells were transfected with Flag-SENP1WT or Flag-SENP1C603S, and mRNA levels of target genes were analyzed by qRT-PCR. Statistical 
significance was determined using Student’s t-test; *P < 0.05 and #P < 0.01 versus Control transfection (without SENP1WT and SENP1C603S).
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These results verify that TBL1 and TBLR1 assembly 
with NF-κB depends on TBL1 SUMOylation. Mutation 
of TBL1 SUMOylation sites attenuated TNF-α-induced 
TBL1 association with RelA, and promoted the strong 
interaction of mutant TBL1 with NCoR or HDAC3. These 
results indicate that SUMOylation of TBL1 and TBLR1 
at Lys560 and Lys497, respectively, is required for TNF-
α-induced TBL1 and TBLR1 assembly with NF-κB and 
NCoR corepressor complex disassembly.
We tested the effect of SENP1 overexpression on 
formation of the TBL1-NF-κB complex. Active SENP1 
substantially induced TBL1 dissociation from NF-κB and 
association with the NCoR/HDAC3 corepressor complex, 
whereas inactive SENP1C603S did not have these effects 
(Figure 4B). These combined results indicate that TBL1/
TBLR1 SUMOylation has a crucial role in formation of 
the TBL1SUMO-TBLR1SUMO-NF-κB coactivator complex 
during inflammatory stimulation.
TBL1 and TBLR1 SUMOylation enhances 
recruitment of the TBL1sUMO-TBLR1sUMO-NF-κB 
complex to the IL-6 and IL-8 promoter
During immune responses, NF-κB is translocated 
into the nucleus where it binds to specific sites of 
cytokine genes such as IL-6, IL-8, and IL-1β [24– 26]. 
Recent work also showed that TBL1 and NF-κB 
specifically bind to the promoter regions of NF-κB 
target genes in an inflammation signal-dependent 
manner. Therefore, we examined whether SUMOylation 
of TBL1 and TBLR1 enhances recruitment of the 
TBL1-TBLR1-NF-κB complex to the NF-κB-binding 
sites of cytokine genes. TNF-α treatment efficiently 
induced NF-κB and TBL1-TBLR1 binding to the NF-
κB-binding region of IL-6 and IL-8. Conversely, reChIP 
experiments showed that TBL1SUMO-TBLR1SUMO formed 
a complex with NF-κB, and the complex bound to the 
NF-κB-binding region of IL-6 and IL-8 (Figure 5A). 
Overexpression of wild-type TBL1 enhanced NF- κB 
binding to the IL-6 promoter and dramatically 
increased histone H3 acetylation in this region, whereas 
SUMOylation-defective TBL1 mutants did not exhibit 
these effects. We observed the same effects in IL-8 
promoter ChIP assay (Figure 5B). These data suggest 
that TBL1 SUMOylation triggers formation of an NF-
κB-TBL1 complex in the promoter regions of NF-κB 
target genes. ChIP assays indicated that SENP1WT 
overexpression induced TBL1-TBLR1-NF-κB complex 
dissociation from the NF-κB-binding sites of cytokine 
genes, whereas overexpression of inactive SENP1C603S 
did not significantly affect TBL1-TBLR1-NF-κB 
complex binding to cytokine genes. These combined 
results indicate that TBL1 and TBLR1 deSUMOylation 
attenuate cytokine signaling by inducing TBL1-TBLR1-
NF-κB complex dissociation from the NF-κB-binding 
sites of cytokine genes (Figure 5C).
TBL1 and TBLR1 deSUMOylation suppress 
PC-3 proliferation
PC-3 cell line is a representative model for androgen-
independent prostate cancer. NF-κB is constitutively active 
in PC-3 and DU145 AIPC cell lines, whereas only very low 
levels of NF-κB activity are detected in the LNCaP ADPC 
cell line. These observations suggest that constitutive 
NF- kB activation may have a role in the survival of 
AIPC cells [10, 11]. We examined whether reduced TBL1 
levels or TBL1-TBLR1 deSUMOylation attenuated 
anchorage-independent growth, which typically correlates 
with in vivo tumorigenic phenotype. PC-3 proliferation 
was substantially lower after TBL1 knockdown than 
in cells transfected with control short hairpin RNA 
(shRNA) (Figure 6A). Overexpression of TBL1WT or 
TBLR1WT enhanced PC-3 cell growth compared with 
overexpression of TBL1K560R or TBLR1K497R (Figure 6B, 
left panel). Expression of TBL1K560R reduced PC-3 cell 
growth and colony formation, whereas expression of 
SUMO-conjugated TBL1K560R restored PC-3 cell growth 
and colony formation (Figure 6B). TBLR1 behaved 
similarly to TBL1 in these assays (Figure 6B, right panel). 
Overexpression of wild-type SENP1WT, but not inactive 
SENP1C603S, greatly reduced anchorage-independent PC-3 
cell growth, indicating the functional relevance of TBL1-
TBLR1 SUMOylation for tumorigenic growth of PC-3 
cells (Figure 6C, 6D). These combined results indicate that 
TBL1-TBLR1 SUMOylation enhances NF-κB-mediated 
inflammatory signaling and proliferation of androgen-
independent prostate cancer cells.
DIscUssION
NF-κB, a transcriptional factor, is strongly activated 
at sites of inflammation, which plays critical role in variety 
of gene expression including cytokines [24]. A recent 
study reported that TBL1 was required for p65 recruitment 
to NF-κB-targeted gene promoters in response to TNF-α 
[23], which suggests an additional role for TBL1 as a 
transcriptional activator. In that study, TBL1 recruitment 
to NF-κB-targeted gene promoters was considered a 
critical step for the transcriptional activation of target 
genes. However, the molecular mechanism underlying 
NF-κB activation by the well-known TBL1 corepressor 
has not been fully elucidated.
In this study, we present evidence that SUMOylation 
of TBL1 and TBLR1 enhances association with NF-κB in 
response to TNF-α, and induce dissociation of the NCoR-
TBL1-TBLR1 corepressor complex. Our group previously 
reported that SUMOylation of TBL1 and TBLR1 promotes 
β-catenin-mediated Wnt signaling via disassembly of 
NCoR-TBL1 corepressor complex. We observed that TBL1 
and TBLR1 are SUMOylated at lysine 560 and lysine 
497, respectively, in response to cytokine signaling, and 
are deSUMOylated by SENP1. SENP1 overexpression 
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suppresses the coactive function of TBL1 and TBLR1 in 
NF-κB-mediated transcriptional regulation of cytokine gene 
expression, which is similar to the effects of Wnt signaling. 
Therefore, this study provides additional evidence that TBL1 
and TBLR1 SUMOylation induce the functional exchange 
of TBL1 and TBLR1 from corepressor to coactivator 
activity via disassembly of the NCoR corepressor complex.
Chronic inflammation is linked to carcinogenesis 
in several organ systems [1], and prostate cancer is 
strongly correlated with chronic inflammation [5]. There 
is accumulating evidence that elevated serum IL-6 levels 
are associated with advanced tumor stages in patients 
with prostate cancer [27]. Elevated NF-κB and IL-6 levels 
have been correlated with drug resistance of prostate 
cancer cells [9, 11]. For example, IL-6 is an autocrine 
and paracrine growth factor for prostate cancer cell lines 
and functions as a resistance factor for cisplatin-mediated 
cytotoxicity [14]. Clinical trials reported that antibody-
targeted IL-6 therapy may be useful for improving 
the performance of other chemotherapy agents during 
treatment of metastatic castration-resistant prostate cancer 
[28]. These combined results suggest that suppression of 
IL-6 levels may be a potential therapeutic strategy for 
treating prostate cancer. We also observed constitutively 
elevated levels of cytokines IL-6, IL-8, and IL-1β in PC-3 
compared with the levels in LNCaP cells, indicating that 
NF-κB is constitutively activated in PC-3 cells. This result 
is consistent with previous studies reporting that NF-κB 
is constitutively activated in androgen-independent PC-3 
prostate cancer cells but not in androgen-dependent 
LNCaP prostate cancer cells. TBL1/TBLR1 SUMOylation 
is elevated in AIPC PC-3 cells compared with that in 
LNCaP cells and the LNCaP-derived AIPC cell line 
C4-2B. SUMOylation of TBL1 and TBLR1 is closely 
correlated with NF-κB activity. Furthermore, this study 
shows direct evidence that sumolyated TBL1 and TBLR1 
are recruited to promoters of both IL-6 and IL-8 under 
inflammation, whereas defective form of SUMOylation 
of TBL1, TBL1K560R, fails to recruit NF-kB to the 
promoters, which means SUMOylated TBL1 and TBLR1 
upregulate the IL-6 and IL-8 promoter through recruiting 
NF-kB to the kB binding regions of two genes.
Overexpression of active SENP1, but not inactive 
SENP1, dramatically suppresses TBL1/TBLR1-mediated 
NF-κB activity and PC-3 cell proliferation. These results 
suggest another possible link between TBL1/TBLR1 
SUMOylation and inflammatory signaling during 
tumorigenic growth of AIPC cells. There is additional 
evidence that the E2 ligase Ubc9 is strongly expressed 
in primary prostate tumor and cancer cells but not in 
metastatic prostate tumors [29, 30]. Our results indicate 
that SUMOylation of TBL1 and TBLR1 may contribute to 
AIPC cell proliferation after androgen withdrawal. Further 
studies are needed to completely elucidate these processes.
Figure 4: TBL1 SUMOylation enhances formation of the TBL1sUMO-NF-κB complex. (A) TNF-α-induced TBL1 SUMOylation 
at Lys560, is required for enhanced TBL1 association with NF-κB. PC-3 cells were co-transfected with the indicated plasmids, treated with 
or without TNF-α for 1 hour, and then harvested. Cell lysates were immunoprecipitated and subsequently immunoblotted with the indicated 
antibodies. (b) SENP1-mediated TBL1 deSUMOylation induces disassembly of the TBL1-NF-κB complex. PC-3 cells were co-transfected 
with the indicated plasmids. Cell lysates were immunoprecipitated and subsequently immunoblotted with the indicated antibodies.
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Figure 5: TBL1 and TBLR1 SUMOylation enhance recruitment of the TBL1-TBLR1-NFκB complex to the IL-6 and 
IL-8 promoter. (A) TNF-α treatment induces recruitment of the TBL1SUMO-TBLR1SUMO-NF-κB complex to the IL-6 and IL-8 promoter 
regions. Cells were treated with 10 ng/ml TNF-α for 1 hour, ChIP and reChIP assays were performed with the indicated antibodies. Error 
bars represent standard deviation (SD, n = 3). Statistical significance was determined using Student’s t-test; #P < 0.01 versus treatment 
without TNF-α. (b) TBL1 SUMOylation enhances NF-κB binding to chromatin at the IL-6 and IL-8 promoter. PC-3 cells were transfected 
with the indicated plasmids, followed by ChIP assays with the indicated antibodies. Error bars represent SD (n = 3). Statistical significance 
was determined using Student’s t-test; #P < 0.01 versus Flag-TBL1 without TNF-α treatment. (c) SENP1-mediated TBL1 and TBLR1 
deSUMOylation induces dissociation of the TBL1-TBLR1-NFκB complex from promoters of NF-κB target genes in PC-3 cells. PC-3 cells 
were transfected with plasmids carrying SENP1WT and/or SENP1C603S. Cell lysates were immunoprecipitated and then used for performing 
ChIP assays with the indicated antibodies. Error bars represent SD (n = 3). Statistical significance was determined using Student’s t-test; 
*P < 0.05 and #P < 0.01 versus transfection of Flag-TBL1 without TNF-α treatment.
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Figure 6: Inhibition of TBL1 and TBLR1 SUMOylation reduces PC-3 cell growth. (A) TBL1 knockdown greatly reduces 
anchorage-independent PC-3 cell proliferation. PC-3 cells were infected with lentiviral shTBL1 to generate TBL1 knockdown lines. 
Knockdown efficiency was measured by RT-PCR and qRT-PCR (left panel) compared to shCon cell lines; shCon or shTBL1 cells were 
seeded with the same cell numbers, and plates were photographed after 3 weeks. (b) TBL1 and TBLR1 SUMOylation enhance tumorigenic 
growth of PC-3 prostate cancer cells. PC-3 cells were co-transfected with TBL1 (left panel) or TBLR1 (right panel) plasmids, and the 
numbers of cells in soft agar were determined under a microscope 2 days after transfection. Data represent the means ± SD of at least three 
independent experiments. Statistical significance was determined using Student’s t-test; #P < 0.01 versus Control. (c, D) SENP1 suppresses 
tumorigenic growth of PC-3 cells. SENP1 knockdown greatly increased anchorage-independent PC-3 cell proliferation (C). PC-3 cells 
were infected with lentiviral shSENP1 to generate SENP1 knockdown cell lines; shCon or shSENP1 cells were seeded with the same cell 
numbers onto media with or without TNF-α (changed every day), allowed to grow for 3 weeks, and then plates were photographed. PC-3 
cells were transfected with SENP1WT or SENP1C603S as indicated, and the numbers of cells in soft agar were determined under a microscope. 
Data represent the means ± SD of at least three independent experiments. Statistical significance was determined using Student’s t-test; 
*P < 0.05 versus Control (D).
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In conclusion, our study identified a SUMOylation-
dependent regulatory mechanism of inflammatory signaling 
in androgen-independent prostate cancer cells. TBL1 
and TBLR1 were reversibly SUMOylated in response 
to inflammatory stimuli, which induced transcriptional 
activation of inflammatory cytokines by formation of the 
TBL1SUMO-TBLR1SUMO-NF-κB complex. We showed that 
inhibition of TBL1-TBLR1 SUMOylation significantly 
suppressed cytokine production and proliferation of androgen-
independent prostate cancer cells. Therefore, our study 
provided important insights into inflammation-promoted 
prostate tumorigenesis and targets for treating AIPC.
MAtErIALs AND MEtHODs
Cell culture, plasmids, and reagents
C4-2B cell lines were purchased from Leland 
Chung’s group at MD Anderson (Houston, TX, USA). 
C4- 2B, LNCaP, and PC-3 human prostate cancer cell 
lines were cultured in Roswell Park Memorial Institute 
1640 medium (RPMI-1640, Hyclone Cell Culture Media, 
GE Healthcare, UT, USA) supplemented with 10% (v/v) 
fetal bovine serum (FBS, Hyclone Cell Culture Media, GE 
Healthcare), and 1% antibiotics and antimycotics (Hyclone 
Cell Culture Media, GE Healthcare). All cell lines were 
cultured at 37ºC in 5% CO
2
. Human recombinant TNF-α 
was purchased from ProSpec (Rehovot, Israel), and 
prepared as 100 μg/ml stocks in sterile H2O (18 MΩ·cm). 
10 ng/ml concentration of TNF-α was used to treat the 
cells during indicated time point. Preparation of full-
length TBL1, TBL1K560R, SUMO-TBL1K560R, TBLR1, 
TBLR1K497R, SUMO-TBLR1K497R, and SUMO1 was 
described previously [21]. SENP1 clones were obtained 
from the 21 C Human Frontier Human Gene Bank 
(Daejeon, Korea), and were subcloned by inserting 
the PCR amplification product into the plasmid pSG5-
KF2M1. All plasmid constructs were verified by DNA 
sequencing. The retroviral-based mammalian expression 
vector pBabe was used to stably express wild-type TBL1/
TBLR1, mutant TBL1/TBLR1, SUMO-fused TBL1/
TBLR1, SENP1, and SENP1C603S protein in PC-3 cells. 
PC-3 cells stably expressing either SENP1 or SENP1C603S 
were generated by puromycin selection. 
Lentiviral short hairpin RNAs
We used shRNAs to establish stable PC-3 cells with 
reduced TBL1 or SENP1 expression. First, two pairs of 
commercially available oligonucleotides encoding each 
target-specific shRNA were purchased (MISSION shRNA, 
Sigma-Aldrich). Next, we prepared lentiviral particles 
using pLKO.1-PURO targeted shRNA, using three 
plasmid co-transfections according to the manufacturer’s 
instructions (Invitrogen, Carlsbad, CA, USA). Then, PC-3 
cells were transfected with lentivirus, incubated for 3 days, 
and lentivirus was isolated from culture medium and 
concentrated with a Centricon-Plus-20 column (Millipore, 
Billerica, MA, USA). Lentivirus PURO shRNA was 
generated as a control.
Immunoprecipitation and immunoblotting
Cells were plated at 60–70% confluency and 
transfected using Lipofectamine 2000 (Invitrogen). Cells 
were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 0.3 M 
NaCl, 1% NP-40, 1 mM PMSF, and protease inhibitor 
mixture). Lysates were clarified by centrifugation at 
13,000 rpm for 20 min at 4°C. Protein concentrations 
were determined spectrophotometrically using the 660 
nm protein assay reagent (Pierce, Rockford, USA). 
Immunoprecipitation (IP) analysis was performed using 
500 μg of whole cell lysate, 15 μl of protein plus A/G 
agarose (Santa Cruz Biotechnology), Flag-M2 agarose 
(Sigma), and commercial antibodies. IP assays were 
incubated overnight with gentle rotation at 4°C. Then, 
immunoprecipitates were washed 3 times in washing 
buffer for 5 min. After the last wash, immunoprecipitates 
were boiled in 5 × SDS loading buffer. Immunoprecipitated 
proteins were analyzed by western blotting. All antibodies 
were commercially available except for antibodies against 
TBL1, TBLR1, and NCoR1. Commercially available 
antibodies were used at dilutions of 1:500 to 1:1,000 
[15, 16]. Monoclonal anti-HDAC3 was obtained from 
BD Transduction Laboratories (Lexington, KY, USA) and 
was used at a dilution of 1:3,000. Polyclonal anti-HDAC3, 
monoclonal anti-Flag, and anti-β-actin antibodies were 
obtained from Sigma and used at a dilution of 1:10,000. 
Anti-SUMO1 and polyclonal anti-Myc antibodies were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) and used at a dilution of 1:500 to 1:2,000. Positive 
signals were developed using Lumi-Light Western Blotting 
Substrate (Roche, Indianapolis, IN, USA) according to the 
manufacturer’s instructions. 
Real-time RT-PCR
Total RNA was isolated from LNCaP, PC-3, and 
C4- 2B cell lines using TRIzol reagent (Takara, Japan). Then, 
cDNAs were synthesized from 3 µg of total RNA using 
Oligo-dT and M-RT reverse transcriptase (Chromogen, 
Seoul, Korea). Real-time qRT-PCR assays were performed 
using ABI PRISM 7000 Sequence Detection System 
instrumentation and software (Applied Biosystems, Foster 
City, CA) according to the manufacturer’s instructions 
with minor modifications. Briefly, the appropriate amount 
of reverse transcription reaction mixture was amplified 
with specific primers using SYBR green PCR master 
mix (Applied Biosystems). Target gene expression levels 
were determined by generating a five-point serial standard 
curve. The singularity and specificity of amplifications 
were checked using dissociation analysis software. All 
reactions were performed in triplicate. Concentrations of the 
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RNA samples were normalized by determining the GAPDH 
mRNA level. The following primers were used: for IL- 6, 
5′-CCCCCAGGAGAAGATTCCAA-3′ (forward) and 5′-GCT 
GCTTTCACACATGTTACTCTTG-3′ (reverse); for IL-1β, 
5′-ACCTGAGCTCGCCAGTGAA-3′ (forward) and 5′-TCG 
GAGATCGTAGCTGGAT-3′ (reverse); for IL-8, 5′-TCCTTG 
TTCCACTGTGCCTTG-3′ (forward) and 5′-TGCTTCCAC 
ATGTCCTCACAAC-3′ (reverse); for TBL1, 5′-CATCTCCA 
TTCTCCAGAAGGG-3′ (forward) and 5′-GTGACAGGG 
ACTCTATGG-3′ (reverse); for GAPDH, 5′-GATGGCATGG 
ACTGTGGTCA-3′ (forward) and 5′- GCAATGCCTCCTG 
CACCACC -3′ (reverse).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays 
were performed with the indicated antibodies as 
described previously [18], but without SDS in all buffers. 
Eluted DNA was amplified with specific primers using 
SYBR green PCR master mix (Applied Biosystems). 
The primers used for the IL-6 gene promoter NF- κB 
binding site were 5′-CCCACCCTCCAACAAAGATT-3′ 
(forward) and 5′-GCTCCAGAGCAGAATGAGCTA-3′ 
(reverse); for IL-8 gene promoter were 5′-GGGCCATC 
AGTTGCAAATC-3′ (forward) and 5′-GGAAGAAACCA 
CCGGAAGGAA-3′ (reverse).
Colony formation
Cells were suspended in RPMI-1640 medium 
containing 10% FBS and 0.3% SeaKem low melting 
temperature agarose. A total of 1 × 103 cells in a volume 
of 15 ml were plated in six-well plates over a 1.5-ml 
layer of solidified RPMI-1640 containing 10% FBS and 
0.6% agarose. The plates were incubated at 37°C for 
3 weeks, and then the colonies formed on each plate were 
photographed from three different views. The numbers 
and sizes of colonies on each plate were counted and 
measured.
Duo-link in situ proximity ligation assay analysis
Duo-link in situ proximity ligation assay (PLA) 
analysis was performed according to the manufacturer’s 
instructions (Olink Biosciences, Uppsala, Sweden). 
Briefly, paraformaldehyde-fixed cells were washed with 
PBS, incubated in 1.5% hydrogen peroxide for 15 min, 
washed, and blocked with blocking solution. Primary 
rabbit antibody was applied, cells were incubated with 
PLUS and MINUS secondary PLA probes against rabbit 
IgG only, or against both rabbit and mouse IgG, and 
then samples were subjected to hybridization, ligation, 
and amplification. Cells were mounted with Duo-link 
mounting medium and examined using an Olympus 
FluoView FV1000 Confocal Microscope (Olympus Corp., 
Tokyo, Japan).
Statistical analysis
Statistical analyses were performed using Student’s 
t-test with Bonferroni for multiple comparisons. A p-value 
less than 0.05 was considered as statistically significant.
Abbreviations
TBL1, transducing β-like 1X-linked protein; 
TBLR1, Transducin β-like 1X-linked receptor 1; NF-κB, 
nuclear factor kappa-light-chain-enhancer of activated B 
cells; SENP1, Sentrin-specific protease 1; HDAC, Histone 
Deacetylase.
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